A lipid lover's guide to novel therapeutics for lipid and cardiovascular risk reduction

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipidology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Low-density lipoprotein cholesterol (LDL-C) reduction is a primary strategy for CVD prevention.
• Emerging evidence highlights other atherogenic particles as therapeutic targets.

Purpose of the Study:

• To review novel therapeutics targeting lipids and lipoproteins for cardiovascular risk reduction.
• To discuss emerging and recently approved therapies for CVD prevention.
• To provide an overview of mechanisms, clinical trial data, and expected effects of these novel agents.

Main Methods:

• Literature review of novel therapeutics in development or recently approved.
• Analysis of clinical trial data for efficacy and safety.
• Synthesis of current knowledge on lipid and cardiovascular risk reduction strategies.

Main Results:

• Several novel therapeutic targets beyond LDL-C are identified, including triglycerides, high-sensitivity C-reactive protein, apolipoprotein A, apolipoprotein C3, and lipoprotein(a).
• Emerging therapies demonstrate potential for significant cardiovascular risk reduction.
• Approved and investigational treatments offer diverse mechanisms of action.

Conclusions:

• Novel lipid-targeting therapeutics represent a significant advancement in CVD prevention and treatment.
• Targeting multiple atherogenic particles offers a promising strategy for comprehensive cardiovascular risk management.
• Further research and clinical application of these therapies are expected to reduce the burden of CVD.